NeuroBo Pharmaceuticals Receives Safety Review Committee Approval To Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH
NeuroBo Pharmaceuticals 获得安全审查委员会的批准,将继续进行评估 DA-1241 治疗麻疹的 2a 期临床试验
NeuroBo Pharmaceuticals Receives Safety Review Committee Approval To Continue With Its Phase 2a Clinical Trial Evaluating DA-1241 For Treatment Of MASH
NeuroBo Pharmaceuticals 获得安全审查委员会的批准,将继续进行评估 DA-1241 治疗麻疹的 2a 期临床试验
使用浏览器的分享功能,分享给你的好友吧